TheraRadar
← Back
Data updated: May 30, 2026

BIOMARIN PHARM

Biotech
Pharmaceuticals Execution: Fair

BIOMARIN PHARM is a biotechnology company with 7 FDA-approved products.

2003
Since
7
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules 4 Biologics

FDA Novel Drug Designations

(2017-2021)
3 Novel 3 First-in-Class 3 Orphan 1 Breakthrough 1 Accelerated 3 Priority Review 1 Fast Track
See 3 novel approvals →
2021 VOXZOGO (VOSORITIDE) First-in-Class · Orphan · Priority Review · Accelerated
2018 PALYNZIQ (PEGVALIASE-PQPZ) First-in-Class · Orphan · Priority Review · Fast Track
2017 BRINEURA (CERLIPONASE ALFA) First-in-Class · Orphan · Breakthrough · Priority Review

BIOMARIN PHARM at a Glance

  • Growing R&D activity with 9 trials in last 2 years

BIOMARIN PHARM's Recent FDA Approvals

New NDA/BLA approvals for BIOMARIN PHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BIOMARIN PHARM's Therapeutic Areas

Disease areas where BIOMARIN PHARM has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

BIOMARIN PHARM Pipeline Snapshot

Active clinical trials for BIOMARIN PHARM across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • VOXZOGO leads revenue
  • • 4 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 13/20 completed
  • • Speed: 44 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges